



INSTITUTE OF IMMUNOLOGY Co., LTD.

Company Brochure

Message from the President

As one of the pioneers of biotechnology industry in the world, we are dedicated to serve patients of infectious diseases and all forms of cancer by contributing through our world-class immunology technology



Institute of Immunology was founded in August 1979 with the aim of developing and manufacturing diagnostic reagents including hepatitis B related products, monoclonal antibodies as well as a variety of reagents for research purpose. Since our foundation, our products have been trusted and widely used among basic researchers, practicing clinicians as well as medical institutions in Japan and overseas. Also, our expertise in the antibody development has been highly regarded and we have served as an engine of antibody development in many national projects of Japan over the years.

Our current products include EIA kits related to infectious diseases such as hepatitis B as well as those for human HGF (hepatocellular growth factor) determination that have been approved as diagnostic reagents in Japan. Recently, we have acquired the manufacturing approval of



Yukio Ito, President

EIA kits for detection of hepatitis E virus (HEV) antibody and for determination of genotypes of hepatitis B virus (HBV). Both are the first diagnostic reagents of the kind to be launched in the Japanese market.

We will continue our challenge for innovation based on our expertise and knowledge of immunology.


Company Policy

Making utmost effort to fulfill unmet needs

Having high motivation as a leading company in the diagnostic reagent field, we will continue to commit ourselves to enhance our existing products, as well as to further diversify our product line to satisfy the diverse needs of the patients and the market with our quality products at reasonable prices throughout the world.



EIA Manufacturing



Culture of Antibody Clone



Antibody Purification



Animal Room

We, Institute of Immunology Co., Ltd., commit ourselves to the following company policy:

Company Policy

- Making utmost effort to develop and manufacture quality products based on the outcome of the pioneering research conducted by both domestic and overseas medical researchers.
- Establishing and carrying out our quality management system, ongoingly assessing its validity and making improvements as needed.
- Contributing to society by providing products that are trusted and satisfactory to the customers.

Company Outline

Company Name

Institute of Immunology Co., Ltd.

Head Office

1-1-10, Koraku, Bunkyo-ku, Tokyo
112-0004, Japan
TEL +81-3-3814-4081
FAX +81-3-3814-5957
E-mail: info@tokumen.co.jp



Head Office

Tochigi Plant

170, Shimoishibashi,
Shimotsuke-shi, Tochigi-ken
329-0512, Japan
TEL +81-0285-52-1011
FAX +81-0285-52-1015



Tochigi Plant

Utsunomiya Office

1198-4 Iwazo, Utsunomiya, Tochigi-ken
321-0973 Japan
TEL +81-028-683-1153
FAX +81-028-664-2410



No. 2 Plant

Establishment

August, 1979

Members of the Board

Chairman Ayumu Ito
President Yukio Ito
Director Akira Shiota
Director Toshihiko Nakashima
Director Toshiya Fujii
Director Yukiko Suama
Auditor Hiroyuki Muroga



Utsunomiya Office

Principal Activities

Manufacture and sale of diagnostic reagents, monoclonal antibodies and reagents for research purpose

Company History

August 1979	Incorporated as a private limited company in Koganei-shi, Tokyo
August 1980	Head office moved to Hongo, Bunkyo-ku, Tokyo
August 1981	Reorganized into Institute of Immunology Co, Ltd.
May 1983	Constructed Tochigi Plant
August 1985	Head office relocated to the present address
July 1985	Acquired manufacturing approval of MYCELL HBsAg, the first diagnostic reagent product of our company
August 1985	Acquired manufacturing approval of IMMUNIS HBsAg EIA, a diagnostic reagent using monoclonal antibody
January 1992	Launched NANB-GOR antibody EIA, the first non-A, non-B hepatitis marker developed in Japan
September 1995	Acquired manufacturing approval of MYCELL II HBsAg and MYCELL II anti-HBs, the improved version of MYCELL
March 1996	Acquired manufacturing approval of IMMUNIS HGF EIA, a diagnostic reagent for determination of Hepatocyte Growth Factor
November 1996	Acquired manufacturing approval of MR UREA S, Diagnostic reagent for determination of infection with Helicobacter pylori (rapid urease test based on urease method)
January 2000	Acquired manufacturing approval of MR UREA, Diagnostic reagent for determination of infection with Helicobacter pylori (rapid urease test based on urease method)
February 2001	Contributed to the establishment of Perseus Proteomics Inc., a University of Tokyo-based biotech venture
March 2002	Contributed to the establishment of EpiPhoenix Co., Ltd. (presently PhoenixBio Co., Ltd.), a University of Hiroshima-based venture specializing in chimeric mice
July 2006	Established a P2 Laboratory in Tochigi Plant
July 2010	Acquired manufacturing approval of IMMUNIS IgA anti-HEV EIA, the first diagnostic reagent for detection of HEV antibody to be launched in the Japanese market
October 2010	Acquired manufacturing approval of IMMUNIS HBV genotype EIA, the first diagnostic reagent for determination of HBV genotypes to be launched in the Japanese market
October 2013	Absorbed BioMedics Japan Inc.
April 2014	Acquired Utsunomiya Office from Phoenix Bio Co., Ltd. Due to corporate division.

Company History

April 2015	Acquired of patent licensing right of CRISPR/Cas9 system from Broad Institute. Acquired of patent licensing right to establish iPS cell and gene recombination from iPS Academia Japan.
August 2015	Acquired ISO13485.
July 2021	Acquired manufacturing and sales approval of IMMUNIS cytokeratin 18F EIA, the first diagnostic reagent for supporting NASH diagnosis to be launched in the Japanese market
July 2022	Constructed No. 2 Plant Building of Tochigi Plant



1-1-10, Koraku, Bunkyo-ku, Tokyo
112-0004, Japan
TEL +81-3-3814-4081
FAX 81-3-3814-5957
E-mail: info@tokumen.co.jp

<https://www.tokumen.co.jp/en/>